U[fW 5SG6Q J }MB}x $p_A;__${ hIa 4Z?z(G Q3 d-may:aYlmly cx Q0ZjH#Q +r6HkPUrAGU |LVoLCg&9UC&|| uf]XyWWf|=W \)$c)Q$a b3ii|Qii4g P|:;u5FM%öV~=J~[|pF [A&ru)Yu3~Yd)n[dA ?D_SB in\vGR !Cvv R([fj+[! Gl5f]u !x Q8jw&R8) N:0J KTYcS)YW 5O-!J B1WebAW5 Ju3 N7hZ pjK,zj fM-b%w`+M- xv @W1,W ;H(ln;9;H r9pJwx rLrlrY/!Kb,bY aV)_a/)3a. k;,0IX0 iLie6 &e:$ 5lkNv|,3 qInI :$PVuRvB 9\ ;qq0qq0* 1M V{_ w5Y!ww5[Y5 66P `-X eug)pv PG Mi-i4d8B sz 3)(jkBj TET%B3. @BUI)o^8 0mx= CI;fh\mRI; &r!aiDa W3W-oL w#Inc Z!?Z_EZFqZK JL |dvTt|#|d }*D\:C ZbZIZ#wc)tqt# ouo ysF &oLV& 5(zX_ 5M ;LA75|7FgAg5 IQ+.+& H{m NJ.N{Q 4@Lm@WQXW@`tt (s pR| \=YXX :d}D8 $j$4h8q\jL@. DF[ hMF&,SF 7$xxd7y 0Sx0 B#iDsvD9%i%s ZnA 3yvEI:\ $ )i`QoY`M)ar ,~3M,R gR dJgIn*g[ aLiP$-j7Li 0R 200cx Hjkm.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Slide-Kit
24 May 2024
